Castle Biosciences’ DecisionDx-Melanoma Stratifies 5-Year Survival From 70% to 96.7% Within AJCC Stages
Data from 1,868 SEER-linked melanoma patients show the DecisionDx-Melanoma test stratifies five-year melanoma-specific survival within AJCC stages, separating T1 low-risk (96.7%) from high-risk (70.0%) and Stage IIB–III low-risk (87.4%) from high-risk (48.5%) groups. These results could drive more personalized management and test adoption.
1. Data Highlights
Data from 1,868 SEER-linked patients tested with DecisionDx-Melanoma showed significant stratification of five-year melanoma-specific survival within AJCC T categories and substages. T1 patients with low-risk Class 1A results had 96.7% survival versus 70.0% for high-risk Class 2B, while Stage IIB–III low-risk versus high-risk saw 87.4% versus 48.5% survival.
2. Clinical Impact
The gene expression profile test provided biologic insights beyond clinicopathologic staging, enabling clinicians to escalate care for high-risk patients and consider less intensive follow-up for low-risk individuals. These findings support integrating molecular risk data into standard protocols for more precise, risk-aligned management decisions.
3. Commercial Potential
Successful risk stratification demonstrated here could boost DecisionDx-Melanoma adoption in dermatology practices and drive incremental revenue growth for Castle Biosciences. With over 220,000 orders since launch and clinical validation in more than 10,000 samples, expanded use may enhance the company’s diagnostics franchise.